The heartmate™ LVAD Community

Over 27,000 people have received the HeartMate II LVAD. Many of them have celebrated five, and some even 10 or more ReBirthdays.1 A HeartMate LVAD recipient’s ReBirthday is the anniversary of their implant. HeartMate LVAD recipients form a special community that grows daily as the awareness of LVAD therapy also grows.

apply to become a Heartmate™ LVAD ambassador

The HeartMate LVAD Ambassador Program was created as a way to connect heart failure patients with our HeartMate LVAD Community. Ambassadors volunteer their time to share their personal stories and demonstrate the difference a HeartMate LVAD has made in their lives.

Hearing about life with an LVAD from someone who is living with one can be very impactful. Our HeartMate LVAD Ambassadors and their caregivers understand that being an Ambassador is more than a title – it’s a role that can have a positive effect on other patients and the broader healthcare community. Learn more about the HeartMate LVAD Ambassador Program.

learn more!
ambassadors show how

a heartmate™ LVAD has made a difference in their lives.

Photo of people wearing baseball jerseys with 'HeartMate II AllStar' on the front

receive the Heartmate LVad Community newsletter

The quarterly HeartMate LVAD Community Newsletter is for current or prospective HeartMate LVAD patients and their caregivers. In it, you will find interviews with HeartMate LVAD Ambassadors, articles on life with an LVAD, caregiver-focused articles, and tips on things like traveling or exercising with an LVAD. Click here to navigate to the Newsletter Archive.

call 1-855-7-heartmate to subscribe
Spring 2019 newsletter image

find a heartmate™ lvad advanced Heart Failure Center

HeartMate LVADs are available nationwide. To find a HeartMate™ LVAD center near you, click the button or call our information center, below.

Each testimonial relates an account of an individual's response to the treatment. The patient's account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient. 

 

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure.

HeartMate II™ LVAS Indications: The HeartMate II Left Ventricular Assist System is indicated for use as a “bridge to transplantation” for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.

HeartMate 3 and HeartMate II LVAS Contraindications: The HeartMate 3 and HeartMate II Left Ventricular Assist Systems are contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3 and HeartMate II LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 or HeartMate II Left Ventricular Assist System include, but are not limited to those listed below: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS), thromboembolism, pericardial fluid collection, pump pocket or pseudo pump pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) and pump thrombosis.

References:

1. Based on clinical and device tracking data as of April 12, 2019